Entries by moonbase alpha

MISSION Therapeutics wins new Life Science Innovation Award

Recognition of outstanding progress in hitherto challenging therapeutic target area Cambridge UK, 20 March 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, today announces that it has won the new Life Science Innovation Award at […]

MISSION appoints Paul Wallace as Chief Business Officer

Appointment highlights scope and productivity of drug discovery platform Cambridge UK, 16 March 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, announces the appointment of Paul Wallace PhD as Chief Business Officer. Dr Wallace joins […]

MISSION appoints Anker Lundemose as Chief Executive Officer

Appointment strengthens UK drug discovery team for transformational change. Cambridge, UK – 9 January 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, announces the appointment of Dr Anker Lundemose MD PhD as Chief Executive Officer. […]